Why Clinical Trials Matter for Mesothelioma
With approximately 3,000 U.S. diagnoses per year, mesothelioma is too rare to attract the same drug development investment as common cancers. Clinical trials are the primary pathway through which new treatments reach mesothelioma patients. Many trials offer:
- Access to therapies not yet commercially available
- Treatment at no cost (trial sponsor often covers drug costs)
- Closer monitoring and more frequent follow-up
- The opportunity to contribute to future treatment advances
Enrolling in a trial does not mean receiving a placebo instead of treatment. Mesothelioma trials almost always compare a new therapy against the current standard of care or add a new drug to standard treatment.
Current Research Approaches
| Approach | Description | Stage |
|---|---|---|
| CAR-T cell therapy | Patient T cells engineered to target mesothelin (highly expressed in mesothelioma) | Phase I/II |
| Tumor Treating Fields (TTFields) | Optune device applies electrical fields to inhibit tumor cell division | Phase III (STELLAR trial) |
| Tazemetostat | EZH2 inhibitor for BAP1-mutant mesothelioma (a common mutation) | Phase II |
| Amatuximab | Anti-mesothelin antibody; studied with chemotherapy | Phase II |
| Mesothelin vaccine | CRS-207 live attenuated bacteria expressing mesothelin; immune activation | Phase II |
| VEGF inhibitors | Bevacizumab + chemotherapy combinations | Phase II/III |
| Perioperative immunotherapy | Immunotherapy before/after P/D or HIPEC surgery | Multiple Phase II |
How to Find Mesothelioma Trials
ClinicalTrials.gov is the official U.S. registry of clinical trials. To find mesothelioma trials:
- Search for “mesothelioma” as the condition
- Filter by your country and preferred travel distance
- Filter by “Recruiting” status
- Note the NCT number of any trials that interest you
- Contact the trial site’s coordinator to discuss eligibility
Your mesothelioma specialist can also identify relevant trials and facilitate referrals. Major centers like MD Anderson, Brigham and Women’s (Harvard), Memorial Sloan Kettering, and Penn Medicine run the largest number of mesothelioma-specific trials.
Eligibility and the Screening Process
Each trial has inclusion and exclusion criteria. Common requirements include:
- Confirmed mesothelioma diagnosis (specific cell type may matter)
- Performance status score (ECOG 0–1 or 0–2)
- Prior treatment history (some trials are first-line; others require prior chemo)
- Adequate organ function (kidney, liver, bone marrow)
- No autoimmune disease (for immunotherapy trials)
- Tissue available for molecular analysis (fresh or archived biopsy)
If you don’t meet eligibility for one trial, you may qualify for others. Trial eligibility criteria change as trials complete enrollment; check periodically.